InspireMD Reports Third Quarter 2026 Financial Results
Globe Newswire•12/11/2026•16:03 ET
2
Key Highlights
- ➤FDA approved CGuard Prime for TCAR, expanding addressable market by over 35,000 annual procedures
- ➤Q3 revenue $2.242 million, down 11.1% year over year
- ➤Q3 net loss $9.762 million, or $0.12 per share, improved from $12.708 million
- ➤Cash, equivalents and marketable securities fell to $19.246 million from $54.211 million
- ➤U.S. CGuard Prime for TCAR sales expected to commence in fourth quarter 2026
Expert Statements
Marvin Slosman, Chief Executive Officer of InspireMD
“FDA approval of CGuard Prime for TCAR procedures represents a transformative milestone for InspireMD, enabling the launch of our next-generation carotid implant that incorporates the latest carotid technology into a rapidly growing TCAR market”
Marvin Slosman, Chief Executive Officer of InspireMD
“We believe CGuard Prime for TCAR, supported by the results of our CGUARDIANS II pivotal trial, supports our mission to most effectively ‘treat the lesion’ with our advanced carotid implant, and, with its best-in-class evidence, paves the way for our return to the U.S. commercial market, strengthens our competitive position and advances our vision of establishing CGuard Prime as a leading platform for carotid intervention.”
Marvin Slosman, Chief Executive Officer of InspireMD
“Building on this milestone, we remain focused on expanding our product portfolio and pipeline across both TCAR and CAS procedures.”
Marvin Slosman, Chief Executive Officer of InspireMD
“We continue to advance enhancements to our CGuard Prime for CAS delivery system, with submission of a PMA supplement to the FDA anticipated before year-end, while progressing our CGUARDIANS III pivotal trial evaluating our proprietary SwitchGuard neuroprotection system for TCAR procedures.”
Marvin Slosman, Chief Executive Officer of InspireMD
“We are also anticipating the introduction of a proprietary micro puncture kit, designed to support vascular access, a critical step in procedural success.”
Marvin Slosman, Chief Executive Officer of InspireMD
“Together, these initiatives reflect our commitment to building a comprehensive carotid intervention platform, with the goal of providing physicians with a broad range of solutions to address the diverse needs of patients undergoing carotid revascularization.”
- Received FDA approval of CGuard(®) Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market -
- Company to host investor conference call today, November 12(th), at 4:30pm ET -
Get started
Create a free account to read the full story.